Capricor Therapeutics shares rise as FDA decision nears
JOSE LUIS CALVO MARTIN & JOSE ENRIQUE GARCIA-MAURIÑO MUZQUIZ
Capricor Therapeutics (CAPR) shares rose 4.4% in extended trading Tuesday after the biotechnology company reported a wider third-quarter loss and missed Wall Street estimates for revenue and earnings.
The San Diego-based company reported no revenue for the quarter ended Sept. 30, missing
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.